CSPC Pharmaceutical Group (XTER:CVG) EBIT: €510 Mil (TTM As of Dec. 2025)


XTER:CVG CSPC Pharmaceutical Group Ltd XTER:CVG
88 GF Score
Price €0.40
GF Value €0.40
! 4 Warning Signs
View Full Analysis

What is CSPC Pharmaceutical Group EBIT?

CSPC Pharmaceutical Group XTER:CVG 88 EBIT is €510 Mil as of Dec. 2025. GuruFocus rates XTER:CVG with a GF Score™ of 88/100 and a GF Value™ of €0.40. The stock has 4 warning signs investors should review.

CSPC Pharmaceutical Group's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was €62 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €510 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. CSPC Pharmaceutical Group's annualized ROC % for the quarter that ended in Dec. 2025 was 6.81%. CSPC Pharmaceutical Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 14.59%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. CSPC Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 6.55%.

CSPC Pharmaceutical Group  (XTER:CVG) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

CSPC Pharmaceutical Group's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=356.472 * ( 1 - 32.76% )/( (0 + 3517.655)/ 1 )
=239.6917728/3517.655
=6.81 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0 - 0 - ( 0 - max(0, 0 - 0+0))
=0

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5662.202 - 1069.592 - ( 1074.955 - max(0, 1234.084 - 2697.925+1074.955))
=3517.655

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

CSPC Pharmaceutical Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=248.492/( ( (0 + max(0, 0)) + (1703.09 + max(-89.792, 0)) )/ 1 )
=248.492/( ( 0 + 1703.09 )/ 1 )
=248.492/1703.09
=14.59 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(579.446 + 374.757 + 134.263) - (1069.592 + 0 + 108.666)
=-89.792

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

CSPC Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=510.107/7782.639
=6.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSPC Pharmaceutical Group EBIT Related Terms

CSPC Pharmaceutical Group EBIT Historical Data

* Premium members only.

The historical data trend for CSPC Pharmaceutical Group's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSPC Pharmaceutical Group EBIT Chart

CSPC Pharmaceutical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 952.45 1,030.04 952.33 737.48 587.67

CSPC Pharmaceutical Group Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 230.03 161.38 142.93 62.12 143.67

XTER:CVG vs LLY, JNJ, ABBV: EBIT Comparison

For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CSPC Pharmaceutical Group EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where CSPC Pharmaceutical Group's EV-to-EBIT falls into.


XTER:CVG
88GF Score
CSPC Pharmaceutical Group Ltd XTER:CVG
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CSPC Pharmaceutical Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €510 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €510 Mil mean?
CSPC Pharmaceutical Group (XTER:CVG) has a EBIT of €510 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on CSPC Pharmaceutical Group.
Is CSPC Pharmaceutical Group's EBIT too high?
CSPC Pharmaceutical Group's current EBIT is €510 Mil. Overall, CSPC Pharmaceutical Group has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does CSPC Pharmaceutical Group's EBIT compare to LLY and JNJ?
CSPC Pharmaceutical Group's EBIT of €510 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on CSPC Pharmaceutical Group. CSPC Pharmaceutical Group's current EBIT is €510 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSPC Pharmaceutical Group stock overvalued right now?
CSPC Pharmaceutical Group (XTER:CVG) has a current EBIT of €510 Mil. The stock's GF Value™ is €0.40, compared to a current price of €0.40 — trading right at its estimated fair value. The current EBIT is €510 Mil. CSPC Pharmaceutical Group's overall GF Score™ is 88/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For CSPC Pharmaceutical Group (XTER:CVG), the current EBIT is €510 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CSPC Pharmaceutical Group (XTER:CVG) Overvalued in 2026?

Based on GuruFocus' analysis, CSPC Pharmaceutical Group stock appears to be undervalued. The current stock price of €0.40 is trading 0% below its estimated GF Value™ of €0.40.

Key valuation signals for XTER:CVG:

  • EBIT: €510 Mil
  • GF Value™: €0.40 vs. price of €0.40 (0% below fair value)
  • GF Score™: 88/100 with 4 warning signs

No single metric tells the full story. See the XTER:CVG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CSPC Pharmaceutical Group Business Description

Address No.896 Zhongshandong Street, Gaoxin District, Hebei Province, Shijiazhuang, CHN, 050035
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
88GF Score

Get the complete analysis for XTER:CVG

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.40
Price
€0.40
GF Value